TY  - GEN 
AU  - Marsal, J.
AU  - Barreiro de Acosta, Manuel
AU  - Blumenstein, I.
AU  - Cappello, M.
AU  - Bazin, T.
AU  - Sebastian, S.
PY  - 2022
SN  - 2296-858X
UR  - http://hdl.handle.net/20.500.11940/20578
AB  - Anti-tumor necrosis factor (anti-TNF) therapy has been successfully used as first-line biologic treatment for moderate-to-severe inflammatory bowel disease (IBD), in both "step-up" and "top-down" approaches, and has become a cornerstone of IBD...
LA  - eng
TI  - Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
DO  - 10.3389/fmed.2022.897936
KW  - AS Santiago
KW  - CHUS
KW  - IDIS
VL  - 9
ER  -